JUAN ESTEBAN-ALTIRRIBA was bor n in 1932 in
. Doctor among them. In consequence a specific uterine beta-mimetic drug does not exist. For this purpose of avoiding this difficulty, ESKES et al. [4] in 1965 suggested the use of a beta-blocker with the aim of obtaining a cardiospecificity in the blockade, but for the reasons mentioned above, the possible existence of a site-specific blocker is also very doubtful. In fact, working with isoproterenol MAHON et al. [9] could not find the selectivity of beta-receptors in vessels and uterus. At this point, the only possibility of interfering with the beta-mimetic effects at different levels would be the existence of differences either qualitative or quantitative in the competition between beta-mimetic and beta-blocker at the receptor binding site of the different Organs. This could explain the close relation existing between the cardiospecificity of some betablockers, claimed to be cardiospecific, and the doses used. That is, when used at therapeutical doses, they do not apparendy evoke extracardiac effects, which appear only when the doses used result in a Stimulation of the sites located in other organs. The purpose of the present study is the search for a dose of a beta-blocker, being active at cardiovascular level without impairing the desired beta-mimetic effect at uterine level.
Material and methods
The present study was carried out on 12 patients in labor. The criteria for admission to the study were the following: 38-42 weeks o£ a normal pregnancy, normal maternal electrocardiogram, uterine activity over 100 Montevideo Units (M. U.), cervical dilatation between 3 and 5 cm, ruptured membranes, cephalic presentation, a period of fasting of at least 8 hours, no medication before and during the investigation, and no signs of fetal distress. In all cases the following variables listed with the corresponding methods were studied: a) Intraamniotic pressure was registered using a Teflon open-tip catheter transvaginally inserted in the amniotic sac filled with saline and connecting its free end to a STATHAM pressure transducer. b) Maternal heart rate (MHR) was obtained with a continuous cardiotachometric recorder, triggered by the R wave of the maternal electrocardiogram obtained with skin electrodes. c) Maternal electrocardiogram (MECG) was also continuously recorded. d) Fetal heart rate (FHR) was obtained with a continuous electrocardiotachometer triggered by the R wave of the fetal electrocardiogram, using a scalp electrode. The above variables were recorded with a BECKMAN multichannel polygraph (R 4 II). e) Maternal blood pressure was measured before, during and after the infusion of the drugs to the mother, using the indirect auscultatory method. f) Fetal capillary pH. Fetal blood samples were obtained before, during and after the infusion of the drugs to the mother, by SALING'S technique [9] using previously heparinized glass pipettes. The actual pH was determined immediately after obtaining the samples with a glass microelectrode (AsTR.up-RADIOMETER) . g) Maternal pH of the antecubital venous blood was determined before, during and after ,the infusion of the drugs.
In some cases, äs indicated in the description of the study, venous maternal and capillary fetal blood glucose levels were also determined using the glucose-oxidase method. The drugs used were: Ritodrine HC1*) äs beta-mimetic and Practolol**) äs beta-blocker [l, 3] . The drugs were always administered in saline.
3 Design of the study The present study on the possible use of a betamimetic drug in combination with a beta-blocker can be divided into four successive stages, the characteristics of each being determined by the suggestions arising from the results obtained in the preceding one.
Stage l
The first stage was ündertaken with the aim of elucidating any kind of deleterious side-effects of the administration of such a combination involved. A continuous infusion of the betamimetic drug at doses inducing evident maternal tachycardia, (pulse rate 20% or more over the previous values) was given to the mother. During prolonged infusion, the beta-blocker was infused on two different occasions. The maximum dose of beta-mimetic used was 600 mcg/min and the infusion lasted 60 minutes. The infusions of the beta-blocker lasted 4 and 5 minutes and the total dose was 10 mg. This scheme was used in two cases.
Stage 2
Since no deleterious effects were recorded in this first group, we went further with two other patients in a second one, »trying to determine the uterine activity and side-effects when the beta-mimetic was used together with the same dose of beta-blocker from the beginning, in the belief that the action of the beta-blocker on the uterine Inhibition could be impaired by the great amount of beta-mimetic that reached the receptors in the doses and time administered to the first patients. In order to test this effect the following scheme was designed: Two infusions of the beta-mimetic drug were given to every patient for two periods of 13 and 10 minutes. The lagtime between the *) Pre-Par® = DU-21220 (PHILIPS^DUPHAR, The Netherlands). **) Eraldin® = ICI-125 (ICI-FARMA, S. A., Spain). two infusions was the period necessary for reaching the previous values in MHR and FHR. The second infusion was accompained by an infusion o£ beta-blocker at a dose of l mg/min. In this group we measured the same variables s in the first, but in addition, determinations of fetal and maternal blood glucose were performed before and after the administration of each infusion.
Stage 3
The encouraging results obtained in this group, particularly in respect to glucose levels in fetus and mother suggesting a possible Inhibition of the beta-mimetic effects, prompted us to continue the investigation of the metabolic effects. In order to Support these findings the second part of the protocol described above was applied to six other patients, using lower doses of the betamimetic drug. It consisted of a continuous infusion of the beta-mimetic (Ritodrine, 250 mcg/ min for 10 minutes) in combination with the beta-blocker (Practolol, l mg/min for the same time). The results showed a complete blockade of the beta-mimetic effects, even the desired one and suggested the possibility of an overdose of the beta-blocker (only maternal and fetal glucose showed a pattern of beta-mimetic effect).
Stage 4
To elucidate that point, we repeated the same scheme on two other patients, but using a dose of 0,5 mg/min, for the beta-blocker. Since the results obtained in this last group do not show a definite trend and might be considered controversial, they will be discussed in the "discussion" in more detail. 
Results

Group l
As can be seen in Fig. l the administration of increasing doses of Ritrodine (from 200 mcg/min to 600 mcg/min), leads to the typical effects of the drug, that is maternal tachycardia (from 90-100 beats/min to 120-130 beats/min), fetal tachycardia (from 130-140 beats/min to 150-160 beats/min), slight increase in the maternal blood pressure (from 35 mmHg to 40 mmHg) and a complete Inhibition of the uterine motility. When the beta-blocker was given, the maternal tachycardia decreased (from 134 beats/ min to 120 beats/min), specially for the first administration. There was no significant modification in the maternal pressure. Twelve minutes after the beginning of the first beta-blocker infusion, FHR also decreased (from 155 beats/min to 130 beats/min). Lastly, the uterine activity did not resume.
From the biochemical point of view we have not observed significant changes in maternal and fetal pH. On the other hand, no pathological changes in the MECG were found. Concerning these parameters, similar results were found in the cases of all the groups, Fig. 2 shows the results of the second scheme of treatment. The first Ritrodrine infusion produced maternal tachycardia that rose from a previous value of 88 beats/min to 118 beats/min, when 600 mcg/min of the beta-mimetic drug was infused. Also a slight fetal tachycardia appeared (from 124 beats/min to around 132 beats/min). There was no change in the differential blood pressure. Uterine motility was completely inhibited. When the Ritodrine infusion was repeated in combination with the Practolol infusion, MHR did not increase äs previously. In fäct, it changed When the combination of the beta-mimetic with the beta-blocker was given to the mother, the cardiovascular effects of the first drug were limited. Fig. 3 . The beta-mimetic infusion produced a significant increase in the maternal and fetal blood glucose, but when the drug was given in combination with the beta-blocker the glucose levels decreased.
Group 2
from 92 beats/min to a maximum of 106 beats/ min. FHR, that had not returned to the values recorded before the first Ritodrine infusion, decreased considerably when the combination of drugs was given to the mother (from 140 beats/ min to 118 beats/min). There was no modification in maternal blood pressure and uterine motility did not resume. It is necessary to say that in the cases of this group, the second part of the scheme was started before the uterine activity reached its previous values. Fig. 3 shows the results obtained in the blood glucose levels in the mother and fetus. As can be seen, the beta-mimetic infusion leads to an im : portant increase in the two values (from 120 mg% to 165 mg% in the mother, and from 80 mg% to 120 mg% in the fetus). When the same dose of beta-mimetic drug was given to the mother simultaneously with the beta-blocker, the maternal and fetal blood glucose decreased from 140 mg% to 130 mg% in the mother, and from 120 mg% to 110 mg% in the fetus. Fig. 4 shows the absence of the beta-mimetic effect on MHR, FHR and uterine motility, when the Ritodrine infusion was simultaneously given to the mother with l mg/min of Practolol; that is the blockade of the beta-mimetic effects. Nevertheless, the typical increase in maternal blood glucose induced by the beta-stimulation appeared in 5 out of the six cases studied, äs shown in In one case (Fig. 7) , during the infusion of the drug combination the uterine motility was inhibited (uterine activity before the infusion = 106.6 M. U.; uterine activity during the infusion = 30.0 M. U.; Inhibition 64.7%).Maternal and fetal tachycardia did not appear and maternal blood glucose did not showan important increase from the previous value during the first 60 minutes (73 mg% before the infusion and 74 and 75 mg%, 30 and 60 minutes later), but rose to 100 mg% in 90 minutes. In contrast, fetal blood glucose rose after the infusion (61 mg% before the infusion and 76, 84 and 73 mg% 30, 60, 90 minutes. later). Also in the other case, neither maternal of fetal heart rate showed tachycardia, with no evaluable change in the maternal blood glucose (65 mg% before the Infusion, 66 mg% 30, 60 and 90 before the infusion and 63, 61, 65 and 61mg% minutes later, and 73mg% 120 minutes later), 30, 60, 90 and 120 minutes later), but uterine fetal blood glucose rose after the infusion (55mg% motility failed to be inhibited ( Fig. 8 and 9 ). . Maternal and fetal blood glucose corresponding to the cases showed in Figs. 7 and 8. As can be seen, maternal blood glucose did not modify but fetal blood glucose increased under the effect of the drugs administered to the mother.
Group 3
Discussion
As can be seen, the plan of the study has been rather unusual äs the eifects studied are in the Although from these studies it was clear that this so-called cardiospecificity was mainly a "cardiopreference", it seemed interesting to us to give a new chance to the ESKES idea of blocking undersirable betamimetic eifects in the use of these drugs in obstetrics. For this reason the two first schemes were designed. The unusual high doses of betamimetic used in these schemes, may seem surprising but we believed that if the selectivity of the beta-blocker existed it would be also apparent in those doses. Since -the beta-blocker can be a dangerous drug, it seemed safer to combine its use with its liatural antagonist which, when used in those doses, could prevent any kind of dangerous effect. In fact, äs expected, the administration of the beta-blocker could counteract the beta-mimetic eifects to some extent without impairing its uterine Inhibition. These findings emphasised further the "cardiopreference" that gave rise to the study. Nevertheless, the two cases of the second treatment scheme showed that the 120 J. Pcrinat. Med. 2 (1974) 18 beta-blocker was capable of Inhibition. On the other hand, the fact that maternal and fetal blood glucose did not show the usual increase due to the beta-mimetic action, prompted us to continue the study. When \ve tried to use the same doses of betablocker with clinical doses of the betamimetic drug we saw an almost complete disappearence of the beta-mimetic effects. Meanwhile, maternal and fetal heart rate maintained the normal values; in spite of the beta-mimetic infusion, the uterine activity (the main objective of the beta-mimetic treatment) was not inhibited. However, the metabolic eflfects of the beta-stimulation did not fail to appear. These results lead to the conclusion that this dose of beta-blocker was able to compete at the level of cellular receptors with the beta-mimetic drug to an extent that overwhelmed this assumed preference. The logical inference was the need of decreasing the beta-blocker doses.
When with the same patient we used a dose of the blocker which was half that of the previous one, the hypothesis seemed to be confirmed.
In fact in that case we obtained a desirable uterine Inhibition without maternal and/or fetal tachycardia. On the other hand maternal blood glucose did not change and only fetal blood glucose showed the beta-mimetic effect. That could be due to a lagtime in the effects of the beta-blocker administration to the fetus, and establish the proof of the possibility of a single metabolic response by the fetus to the betamimetic treatment without maternal Variation in blood glucose. When this .experience was repeated in a second case all parameters behaved similarly, except uterine activity which was not inhibited. This raises the problem of individual responses.
Since we are working with the competition at receptor level, the threshold between partial and total competition has to be very slight. For this reason an adequate dose, established individually, would be necessary in the use of these drugs, and need to be investigated. However, another mechanism of action in the effect of the beta-blocker can not be excluded since its administration can impair the beta-mimetic effects obtained by the direct administration of cyclic AMP.
Conclusions
1. To our knowledge the administration of a beta-blocker together with a beta-mimetic to the mother during labor does not evoke deleterious side-effects either in mother or the fetus. 2. The so-called cardiospecific beta-blocker Practolol, has no cardiospecificity resulting in different responses in terms of inhibition of the beta-mimetic effects at metabolic and uterine levels. 3. It seems important to stress that, at least in two cases, fetal blood glucose rose under the effects of the beta-mimetic without any significant increase in maternal blood glucose. It Supports the hypothesis that the increase in blood glucose observed in the fetus in these cases is due to a direct effect of the beta-mimetic drugs on the fetal metabolic receptors rather than a ttansplacental transfer of the maternal glucose. 4. The ability to compete with the beta-mimetic at receptors of some sites elsewhere in the body depends on an individual response to the different sites. It points out the impossibility of establishing fixed doses and limits the clinical use of the beta-blocker.
Summary
The effectiveness of the use of beta-mimetic drugs in obstetrics may be limited by the fact that the Stimulation of the uterine beta-receptors is not specific and is accompanied by the Stimulation of the other beta-receptors elsewhere in the body. The ideal means of avoiding the cardiovascular and/or the metabolic effects of these drugs would be the possibility of obtaining specific stimulators for the different anatomical locations pf the receptors. But, up to the present time, nothing indicates a qualitative differentation among them and, in conseqüence, a specific uterine betamimetic drug does not exist. For the purpose of avoiding this difficulty, ESKES et al. (1965) suggested the use of a beta-blocker'with the aim of obtaining a cardio-specificity in the blockade. The purpose of the present study is the search for a dose of a beta-blocker claimed to be cardio-specific, effective at the cardiovascular level but without impairing the desired beta-mimetic effect at the uterine level. The drugs used were Ritodrine-HCl äs beta-mimetic and Practolol äs beta-blocker. The study was carried out in 12 normal patients in labor, in which the following variables were studied: intraamniotic pressure, maternal heart rate, maternal electrocardiogram, fetal heart rate, maternal blood pressure, fetal capillary pH, maternal venous pH, maternal blood glticose and fetal blood glucose. The study was divided into four successive stages, the characteristics of each one being determined by the suggestions arising from the results obtained in the preceding one.
The results of the study show that the administration of the beta-blocker together with the beta-mimetic to the mother du ring labor does not evoke deleterious side-effects eithet in the mother or the fetus and that the so-called cardiospecific beta-blocker Practolol, äs expected, does not have a cardiospecificity with difTerent responses äs to the Inhibition of the beta-mimetic effects at metabolic and uterine levels (Figs. l to 5) . The ability to compete with the beta-mimetic at the receptors of some anatomical areas depends on an individual response to the different areas; this points out the impossibility of establishing fixed doses and limits the clinical use of the beta-blocker. Finally, from the study of the maternal and fetal blood glucose (Figs. 6 to 9) , it appeared that, at least in some cases, maternal blood glucose did not change and only the fetal blood glucose showed the typical beta-mimetic effect. This fact Supports the hypothesis of a single metabolic response by the fetus to the beta-mimetic treatment.
I. e. the increase in blood glucose in the fetus is due to a direct effect of the beta-mimetic drug on the fetal metabolic receptors rather than a transplacental transfer of the maternal glucose.
Keywords: Beta-blocker, beta-mimetics, (metabolic and cardiovascular effects), glucose, mother, fetus, Practolol, Ritodrine. (Figs. 6-9) , il apparait que dans la plupart des cas, la glycemie maternelle ne change pas, seule la glycemie foetale se modifie sous l'influence specifique de la substance jS-mimetique. Ce fait soutient l'hypothese de l'existence d'une reponse foetale seule, du point de vue metabolique, au traitement ß-stimulant. Ceci suggere que Paugmentation de la glycemie foetale est due ä un effet direct de la drogue sur le metabolisme hydrocarbone du foetus, plutöt qu'ä un passäge transplacentaire du glucose de la mere vers le foetus.
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